Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 33

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 33
---
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:

Level
1 - quoted prices in active markets for identical assets or liabilities.

Level
2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level
3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions).

Earnings
(loss) per Share

Earnings
(loss) per share is computed in accordance with ASC Topic 260, “Earnings per Share”. The basic weighted average number
of shares of common stock outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted
average number of shares outstanding includes such stock options and warrants. During the three and six months ended June 30, 2025
and 2024, outstanding aggregate stock options and warrants of 7,054,227 and 2,824,057,
respectively, were not included in the computation of diluted earnings per share, because to do so would have had an antidilutive
effect.

Recent
accounting pronouncements not yet adopted 

In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature
of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant
line items, including but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide
a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively,
disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses.
This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning
after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of this new guidance to have a material
impact on the consolidated financial statements.

    8

TELOMIR
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

JUNE
30, 2025

(Unaudited)

In
December 2023, the FASB issued ASU 2023-